Comparison of Effect of Budesonide and Systemic Corticosteroids on Acute Exacerbations of COPD:A Meta-analysis

徐飞,崔文强,吴晓,董竞成

DOI: https://doi.org/10.3969/J.iSSn.1007-9572.2015.08.005

2015-01-01

Chinese General Practice

Abstract:Objective To systematically review the efficacy and safety of budesonide ( BUD ) and systemic corticosteroids( sCs)on patients with AECOPD. Methods We searched literature concerning studies in which patients with AECOPD receiving BUD treatment were assigned as trial group and sCs as control group from PubMed,Web of science,CNKI, VIP database and CBM Data with the time range of searching set from establishment of the databases to July 2014. The extracted data covered pulmonary function analysis, arterial blood gas analysis, score of dyspnea, score of CAT and adverse events. Results A total of 19 pieces of valid literature were included. The meta analysis showed that there was no significant difference in FEV1 before and after treatment either in non -seven -day treatment subgroup or seven -day treatment subgroup〔MD =-0. 03,95%CI( - 0. 11,0. 05),P = 0. 45;MD = - 0. 01,95% CI( - 0. 06,0. 03),P = 0. 61〕;there was no significant difference in FEV1% before and after treatment either in non-seven-day treatment subgroup or seven-day treatment subgroup〔MD= -0. 80,95%CI( -2. 62,1. 02),P =0. 39;MD = -0. 21,95%CI( -1. 44,1. 03),P =0. 74〕;there was significant difference in PaO2 before and after treatment both in non-seven-day treatment subgroup and seven-day treatment subgroup〔MD= -2. 12,95%CI( -4. 14,-0. 10),P=0. 04;MD= -1. 06,95%CI( -1. 85,-0. 26),P=0. 01〕;there was no significant difference in PaCO2 before and after treatment either in non-seven-day treatment subgroup or seven-day treatment subgroup〔MD = -0. 44,95%CI( -1. 13,0. 26),P =0. 22;MD =0. 00,95%CI( -0. 58, 0. 57),P=0. 99〕;there was no significant difference in the scores of dyspnea〔MD= -0. 02,95%CI( -0. 18,0. 13),P=0. 76〕;there was no significant difference in CAT〔MD=0. 34,95%CI( -0. 23,0. 92),P=0. 24〕. For trial group, the adverse events were mainly increasing level of blood glucose,stomach upset and xerostomia;for control group,the adverse events were mainly discomfort in oral cavity,throat and stomach. Conclusion BUD and sCs are both effective in improving pulmonary function and arterial blood gas,alleviating dyspnea and reducing CAT score in patients with AECOPD. The difference in the effects is not statistically significant and BUD causes less adverse events than sCs.